{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:05:45Z","timestamp":1789578345460,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ando.2023.10.003","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T04:17:43Z","timestamp":1697689063000},"page":"727-733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["First evidence of anti-VEGF efficacy in an adult case of adamantinomatous craniopharyngioma: Case report and illustrative review"],"prefix":"10.1016","volume":"84","author":[{"given":"Andrea","family":"De Rosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Calvanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Ducray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Vasiljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Manet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Raverot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Jouanneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2023.10.003_bib0175","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/hed.21771","article-title":"Craniopharyngioma: a pathologic, clinical, and surgical review","volume":"34","author":"Fernandez-Miranda","year":"2012","journal-title":"Head Neck"},{"key":"10.1016\/j.ando.2023.10.003_bib0180","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00701-020-04265-1","article-title":"Surgical management of craniopharyngiomas in adult patients: a systematic review and consensus statement on behalf of the EANS skull base section","volume":"162","author":"Cossu","year":"2020","journal-title":"Acta Neurochir (Wien)"},{"key":"10.1016\/j.ando.2023.10.003_bib0185","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11102-015-0663-4","article-title":"Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor","volume":"19","author":"Aylwin","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2023.10.003_bib0190","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng.2868","article-title":"Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas","volume":"46","author":"Brastianos","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.ando.2023.10.003_bib0195","doi-asserted-by":"crossref","first-page":"djv310","DOI":"10.1093\/jnci\/djv310","article-title":"Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy","volume":"108","author":"Brastianos","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ando.2023.10.003_bib0200","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3389\/fonc.2019.00791","article-title":"Targeting IL-6 Is a potential treatment for primary cystic craniopharyngioma","volume":"9","author":"Grob","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ando.2023.10.003_bib0205","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00401-014-1270-6","article-title":"BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma","volume":"127","author":"Larkin","year":"2014","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ando.2023.10.003_bib0210","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1515\/jpem-2014-0442","article-title":"Adamantinomatous craniopharyngioma: pathology, molecular genetics and mouse models","volume":"28","author":"Martinez-Barbera","year":"2015","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.10.003_bib0215","doi-asserted-by":"crossref","first-page":"882381","DOI":"10.3389\/fendo.2022.882381","article-title":"Neoadjuvant B-RAF and MEK inhibitor targeted therapy for adult papillary craniopharyngiomas: a new treatment paradigm","volume":"13","author":"Calvanese","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ando.2023.10.003_bib0220","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/brainsci13030515","article-title":"Current advances in papillary craniopharyngioma: state-of-the-art therapies and overview of the literature","volume":"13","author":"Jannelli","year":"2023","journal-title":"Brain Sci"},{"key":"10.1016\/j.ando.2023.10.003_bib0225","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.3171\/2016.8.FOCUS16307","article-title":"Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice","volume":"41","author":"Apps","year":"2016","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.ando.2023.10.003_bib0230","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00401-005-1004-x","article-title":"Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region","volume":"109","author":"Buslei","year":"2005","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ando.2023.10.003_bib0235","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00401-010-0642-9","article-title":"Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling","volume":"119","author":"H\u00f6lsken","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ando.2023.10.003_bib0240","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.3171\/2019.10.FOCUS19705","article-title":"Adamantinomatous craniopharyngioma: moving toward targeted therapies","volume":"48","author":"Hengartner","year":"2020","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.ando.2023.10.003_bib0245","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.3171\/2016.9.FOCUS16316","article-title":"Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin","volume":"41","author":"Stache","year":"2016","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.ando.2023.10.003_bib0250","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1158\/1078-0432.CCR-10-2811","article-title":"EGFR signaling regulates tumor cell migration in craniopharyngiomas","volume":"17","author":"H\u00f6lsken","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ando.2023.10.003_bib0255","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00401-012-0957-9","article-title":"Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma","volume":"124","author":"Andoniadou","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ando.2023.10.003_bib0260","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1530\/EJE-14-0934","article-title":"Sonic Hedgehog pathway is upregulated in adamantinomatous craniopharyngiomas","volume":"172","author":"Gomes","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.10.003_bib0265","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/cancers8020022","article-title":"Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors","volume":"8","author":"Rimkus","year":"2016","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ando.2023.10.003_bib0270","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1080\/14728222.2020.1823967","article-title":"The SHH\/GLI signaling pathway: a therapeutic target for medulloblastoma","volume":"24","author":"Lospinoso Severini","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.ando.2023.10.003_bib0275","doi-asserted-by":"crossref","first-page":"8","DOI":"10.17305\/bjbms.2018.2756","article-title":"The role of the Hedgehog signaling pathway in cancer: a comprehensive review","volume":"18","author":"Skoda","year":"2018","journal-title":"Bosn J Basic Med Sci"},{"key":"10.1016\/j.ando.2023.10.003_bib0280","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1200\/JCO.2015.62.8719","article-title":"Randomized phase Ib\/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer","volume":"33","author":"Catenacci","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2023.10.003_bib0285","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/ERC-18-0538","article-title":"SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma","volume":"26","author":"Carreno","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2023.10.003_bib0290","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/neuonc\/noy035","article-title":"Multiplexed immunofluorescence reveals potential PD-1\/PD-L1 pathway vulnerabilities in craniopharyngioma","volume":"20","author":"Coy","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ando.2023.10.003_bib0295","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00381-020-04677-5","article-title":"Adamantinomatous craniopharyngioma in the molecular age and the potential of targeted therapies: a review","volume":"36","author":"Whelan","year":"2020","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.ando.2023.10.003_bib0300","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s00381-010-1245-4","article-title":"The role of inflammation in the genesis of the cystic component of craniopharyngiomas","volume":"26","author":"Pettorini","year":"2010","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.ando.2023.10.003_bib0305","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.3171\/2010.1.FOCUS09310","article-title":"Craniopharyngiomas: intratumoral chemotherapy with interferon-alpha: a multicenter preliminary study with 60 cases","volume":"28","author":"Cavalheiro","year":"2010","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.ando.2023.10.003_bib0310","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00381-005-1226-1","article-title":"Use of interferon alpha in intratumoral chemotherapy for cystic craniopharyngioma","volume":"21","author":"Cavalheiro","year":"2005","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.ando.2023.10.003_bib0315","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1227\/01.NEU.0000367553.65099.14","article-title":"Expression of angiogenic factors in craniopharyngiomas: implications for tumor recurrence","volume":"66","author":"Sun","year":"2010","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ando.2023.10.003_bib0320","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.surneu.2006.05.047","article-title":"Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma","volume":"66","author":"Xu","year":"2006","journal-title":"Surg Neurol"},{"key":"10.1016\/j.ando.2023.10.003_bib0325","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1007\/s11064-011-0560-9","article-title":"Expression of matrix metalloproteinase-9, type IV collagen and vascular endothelial growth factor in adamantinous craniopharyngioma","volume":"36","author":"Xia","year":"2011","journal-title":"Neurochem Res"},{"key":"10.1016\/j.ando.2023.10.003_bib0330","doi-asserted-by":"crossref","first-page":"136","DOI":"10.31083\/j.fbl2704136","article-title":"Targeted therapy in the management of modern craniopharyngiomas","volume":"27","author":"Reyes","year":"2022","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.ando.2023.10.003_bib0335","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/cncr.10281","article-title":"Angiogenesis in patients with craniopharyngiomas: correlation with treatment and outcome","volume":"94","author":"Vidal","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2023.10.003_bib0340","doi-asserted-by":"crossref","first-page":"830793","DOI":"10.3389\/fgene.2022.830793","article-title":"Integrative analysis of biomarkers and mechanisms in adamantinomatous craniopharyngioma","volume":"13","author":"Lin","year":"2022","journal-title":"Front Genet"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426623007126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426623007126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:54:47Z","timestamp":1757717687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426623007126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0003426623007126"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2023.10.003","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First evidence of anti-VEGF efficacy in an adult case of adamantinomatous craniopharyngioma: Case report and illustrative review","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2023.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}